Atrion (NASDAQ:ATRI) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of Atrion (NASDAQ:ATRI) in a research note issued to investors on Friday morning. The brokerage issued a sell rating on the medical instruments supplier’s stock.

Atrion Price Performance

Shares of ATRI opened at $458.30 on Friday. The business has a 50-day moving average of $455.57 and a 200-day moving average of $419.23. The company has a market capitalization of $806.61 million, a price-to-earnings ratio of 43.07 and a beta of 0.69. Atrion has a 1 year low of $274.98 and a 1 year high of $564.21.

Atrion (NASDAQ:ATRI) last issued its quarterly earnings results on Friday, May 10th. The medical instruments supplier reported $1.59 earnings per share (EPS) for the quarter. Atrion had a net margin of 10.60% and a return on equity of 7.75%. The firm had revenue of $47.33 million for the quarter.

Atrion Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 28th. Stockholders of record on Friday, June 14th were paid a $2.20 dividend. This represents a $8.80 dividend on an annualized basis and a dividend yield of 1.92%. The ex-dividend date was Friday, June 14th. Atrion’s dividend payout ratio is 82.71%.

Institutional Investors Weigh In On Atrion

A number of hedge funds have recently added to or reduced their stakes in the business. Wolverine Asset Management LLC bought a new position in shares of Atrion during the 2nd quarter worth approximately $624,000. Versor Investments LP bought a new position in Atrion during the second quarter worth $3,247,000. Principal Financial Group Inc. grew its holdings in Atrion by 12.7% in the second quarter. Principal Financial Group Inc. now owns 681 shares of the medical instruments supplier’s stock worth $308,000 after purchasing an additional 77 shares during the period. Bank of New York Mellon Corp increased its stake in Atrion by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 14,921 shares of the medical instruments supplier’s stock valued at $6,751,000 after purchasing an additional 436 shares in the last quarter. Finally, Comerica Bank raised its holdings in shares of Atrion by 60.9% during the first quarter. Comerica Bank now owns 415 shares of the medical instruments supplier’s stock valued at $192,000 after purchasing an additional 157 shares during the period. 66.19% of the stock is currently owned by institutional investors.

About Atrion

Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments.